Karolina Glanz

Karolina Glanz

Auto-generated profile, based on publicly available information

Karolina Glanz

Max Planck Institute for Infection Biology, Berlin, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMARIATERESA DE CESARE
MARIATERESA DE CESARE
MMMulenga Mwenda
Mulenga Mwenda
AJAnna E. Jeffreys
Anna E. Jeffreys
JCJacob Chirwa
Jacob Chirwa
CDChris Drakeley
Chris Drakeley
JHJason A. Hendry
Jason A. Hendry
Genomic surveillance of Plasmodium falciparum malaria can provide policy-relevant information about antimalarial drug resistance, diagnostic test failure, and the evolution of vaccine targets. Yet the large and low complexity genome of P. falciparum complicates the development of genomic methods, while resource constraints in malaria endemic regions can limit their deployment. Here, we demonstrate an approach for targeted nanopore sequencing of P. falciparum from dried blood spots (DBS) that enables cost-effective genomic surveillance of malaria in low-resource settings. We release software that facilitates flexible design of amplicon sequencing panels and use this software to design two target panels for P. falciparum. The panels generate 3–4 kbp reads for eight and sixteen targets respectively, covering key drug-resistance associated genes, diagnostic test antigens, polymorphic markers and the vaccine target csp. We validate our approach on mock and field samples, demonstrating robust sequencing coverage, accurate variant calls within coding sequences, the ability to explore P. falciparum within-sample diversity and to detect deletions underlying rapid diagnostic test failure.

6 August 2025 in Journal of Infection
Verified
Journal Article
Open access
TBThorsten Brenner
Thorsten Brenner
SDSebastian Oliver Decker
Sebastian Oliver Decker
YVYevhen Vainshtein
Yevhen Vainshtein
SGSilke Grumaz
Silke Grumaz
MMMehdi Manoochehri
Mehdi Manoochehri
HGHans-Jörg Gillmann
Hans-Jörg Gillmann
Despite limited sensitivity and specificity, blood cultures (BCs) still represent the gold standard of diagnostic care in septic patients. We aimed to overcome current diagnostic limitations by unbiased next-generation sequencing (NGS) of circulating microbial cell-free DNA (mcfDNA) in plasma samples. We performed a prospective, observational, non-interventional, multicenter study (Next GeneSiS-Trial) to compare positivity rates for NGS-based identification of causative pathogens with BCs in patients suffering from sepsis or septic shock. An independent expert panel (n=3) retrospectively evaluated the plausibility of NGS-based findings and the potential for anti-infective treatment adaptations based on NGS results. The positivity rate of NGS-based diagnostics (NGS+) for 491 septic patients was 70.5% compared to positive BCs (BC+) with 19.4% within the first three days after sepsis onset. NGS+ results were evaluated as plausible in 98.6% of cases by the expert panel. Based on the experts´ recommendations, additional knowledge of NGS-based pathogen findings would have resulted in anti-infective treatment adaptations in 32.6% of all patients. Potentially inadequately treated NGS+/blood culture negative (BC-) patients showed worse outcomes. The integration of NGS-based pathogen diagnostics in sepsis has the potential to improve patients´ outcomes as compared to a treatment strategy based on standard-of-care microbiological diagnostics alone.

11 May 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMulenga Mwenda
Mulenga Mwenda
KMKarolina Mosler
Karolina Mosler
BBBernd Bohmeier
Bernd Bohmeier
MCMiriam Chomba
Miriam Chomba
WLWelmoed van Loon
Welmoed van Loon
JHJason A. Hendry
Jason A. Hendry
In sub-Saharan Africa, continental-scale genomic surveillance of Plasmodium falciparum malaria is needed to track the spread of drug and diagnostic resistance, as well as monitor parasite evolutionary responses to vaccine rollout. Yet continental-scale implementation is hindered by a lack of genomic approaches suitable for local laboratories, and the vastness of the continent. Here, we initiate a decentralised scale-up of P. falciparum genomic surveillance by locally sequencing and analysing 1065 samples across six African countries in one year. We achieve this with a novel nanopore sequencing protocol that is rapid (~5 hr) and cost-effective (<$25 USD/sample), providing surveillance of antimalarial drug resistance genes, hrp2/3 deletions, the vaccine target csp , and the polymorphic gene ama1 . We couple this to a laptop-based bioinformatics dashboard that runs offline and displays mapping and variant calling results in real-time. We demonstrate robust sequencing coverage across parasitemia levels and laboratories, accurate identification of antimalarial resistance markers and hrp2/3 deletions; and, with a novel variant caller, sensitive detection of mutations carried by minor clones. Our approach will accelerate genomic surveillance of P. falciparum malaria across sub-Saharan Africa at a time of urgent need.

12 February 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
ESEmma Schallenberg
Emma Schallenberg
WLWelmoed van Loon
Welmoed van Loon
DMDjibril Mbarushimana
Djibril Mbarushimana
CIClement Igiraneza
Clement Igiraneza
KGKarolina Glanz
Karolina Glanz
FMFrank P Mockenhaupt
Frank P Mockenhaupt
Background: In many countries in Sub-Saharan Africa, the Plasmodium falciparum chloroquine resistance marker pfcrt K76T disappeared within a decade after use of chloroquine ceased. pfaat1 S258L has recently been implicated as another chloroquine resistance marker. Both genes may affect parasite susceptibility to partner drugs in artemisinin-based combination therapy. Rwanda abolished chloroquine use in 2001, and since 2006 the first-line antimalarial is artemether-lumefantrine. However, partial artemisinin resistance emerged in the region. We assessed the prevalence of pfcrt and pfaat1 markers in Huye district between 2010 and 2023, following trends and updating the status in southern Rwanda. Methods: P. falciparum-positive blood samples from community children and malaria patients collected in 2010, 2014, 2018, 2019, and 2023 were examined. pfcrt K76T was genotyped by restriction fragment length polymorphism, and pfaat1 S258L by high-resolution melting curve (2010–2019). Samples from 2023 were subjected to nanopore sequencing. Results: In 606 samples, pfcrt K76T prevalence declined from 76% (95% confidence interval [CI], 68%–83%) to 18% (95% CI, 11%–25%) between 2010 and 2018 but remained constant since at around 25% (P < .001). No other pfcrt markers were observed. pfaat1 S258L has remained at or near fixation. The artemisinin resistance marker pfk13 R561H was associated with pfcrt K76T (P = .02). Discussion: The persistence of pfcrt K76T 20 years after abolishing chloroquine use indicates ongoing drug selection or importation. The fixation of pfaat1 S258L argues against a major fitness cost of this variant in Huye. Increases in partial artemisinin resistance in Rwanda and molecular markers indicate compromised lumefantrine efficacy. The observed pfcrt and pfaat1 signatures in the study area might be of use in guiding artemisinin partner drug alternatives.